Nanocarrier-based targeted drug delivery for Alzheimer’s disease: addressing neuroinflammation and enhancing clinical translation
Frontiers in Pharmacology · 14.05.2025 · 16
DOI: 10.3389/fphar.2025.1591438 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.05.2025. Verfasst von Kang Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Acupuncture and Moxibustion Department, Beijing Massage Hospital, Beijing, China. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, amyloid-beta (Aβ) aggregation, tau pathology, and chronic neuroinflammation. Among these, neuroinflammation plays a crucial role in exacerbating disease progression, making it an attractive therapeutic target. However, the presence of the blood-brain barrier (BBB) significantly limits the effective delivery of therapeutic agents to the brain, necessitating novel drug delivery strategies. Nanocarrier-based delivery systems have emerged as a promising solution to these challenges, offering targeted drug transport, enhanced BBB penetration, and improved bioavailability while minimizing systemic toxicity. This review explores the current advancements in nanocarrier-mediated drug delivery for AD, focusing on the mechanisms of neuroinflammation, the role of nanocarriers in overcoming the BBB, and their ability to modulate inflammatory pathways. Furthermore, the review discusses preclinical validation strategies and key challenges, including safety concerns, large-scale production limitations, and regulatory hurdles that must be addressed to enable clinical translation. Future perspectives emphasize the integration of nanotechnology with precision medicine, gene therapy, and artificial intelligence to optimize nanocarrier design for individualized AD treatment. By overcoming these obstacles, nanocarriers hold the potential to revolutionize therapeutic approaches for AD and other neurodegenerative diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Acupuncture and Moxibustion Department, Beijing Massage Hospital, Beijing, China.
- Key Laboratory of Medical Electrophysiology, Ministry of Education & Medical Electrophysiological Key Laboratory of Sichuan Province, (Collaborative Innovation Center for Prevention of Cardiovascular Diseases), Institut…
- Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- The school of Clinical Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China.
- Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Rheumatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zitieren
APA
Wang, K., Yang, R., Li, J., Wang, H., Wan, L., & He, J. (2025). Nanocarrier-based targeted drug delivery for Alzheimer’s disease: addressing neuroinflammation and enhancing clinical translation. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1591438
Vancouver
Wang K, Yang R, Li J, Wang H, Wan L, He J. Nanocarrier-based targeted drug delivery for Alzheimer’s disease: addressing neuroinflammation and enhancing clinical translation. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1591438
BibTeX
@article{Wang2025,
author = {Wang, Kang and Yang, Rongying and Li, Jing and Wang, Haitao and Wan, Li and He, Jiale},
title = {Nanocarrier-based targeted drug delivery for Alzheimer’s disease: addressing neuroinflammation and enhancing clinical translation},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1591438}
}
EUVIMED